{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:10:53Z","timestamp":1790100653105,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T00:00:00Z","timestamp":1510185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ab.2017.11.002","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T23:17:24Z","timestamp":1510183044000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis"],"prefix":"10.1016","volume":"540-541","author":[{"given":"Noriko","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2017.11.002_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4161\/mabs.25234","article-title":"Immunogenicity of mAbs in non-human primates during nonclinical safety assessment","volume":"5","author":"van Meer","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.ab.2017.11.002_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.286","article-title":"A phase 1 study comparing the proposed biosimilar BS-503a with bevacizumab in healthy male volunteers","volume":"5","author":"Tajima","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ab.2017.11.002_bib3","first-page":"53","article-title":"Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology","volume":"232","author":"Leveziel","year":"2014","journal-title":"Z. fur Augenheilkd."},{"key":"10.1016\/j.ab.2017.11.002_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcph.818","article-title":"Evaluation of immunogenicity of Nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors","volume":"57","author":"Agrawal","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ab.2017.11.002_bib5","series-title":"U.S. Development of Health and Human Services, Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products","author":"D.A","year":"2016"},{"key":"10.1016\/j.ab.2017.11.002_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.autrev.2015.02.007","article-title":"Managing unwanted immunogenicity of biologicals","volume":"14","author":"Deehan","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ab.2017.11.002_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4155\/bio.13.302","article-title":"Immunogenicity and PK\/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis","volume":"6","author":"Wang","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2017.11.002_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072021","article-title":"Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab","volume":"8","author":"Nugue","year":"2013","journal-title":"PloS one"},{"key":"10.1016\/j.ab.2017.11.002_bib9","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/ac800205s","article-title":"Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS\/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry","volume":"80","author":"Heudi","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2017.11.002_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1039\/C3AN02104A","article-title":"Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis","volume":"139","author":"Iwamoto","year":"2014","journal-title":"Analyst"},{"key":"10.1016\/j.ab.2017.11.002_bib11","doi-asserted-by":"crossref","first-page":"9177","DOI":"10.1039\/C5AY01588J","article-title":"The development of the validated LCMS bioanalysis of trastuzumab in human plasma using a selective detection method for complementarity-determining regions of monoclonal antibodies: nano-surface and molecular-orientation limited (nSMOL) proteolysis","volume":"7","author":"Iwamoto","year":"2015","journal-title":"Anal. Methods"},{"key":"10.1016\/j.ab.2017.11.002_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dmpk.2015.11.004","article-title":"Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis","volume":"31","author":"Iwamoto","year":"2016","journal-title":"Drug Metabolism Pharmacokinet."},{"key":"10.1016\/j.ab.2017.11.002_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchromb.2016.04.038","article-title":"Validated LC-MS\/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis","volume":"1023\u20131024","author":"Iwamoto","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ab.2017.11.002_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrrheum.2009.212","article-title":"Therapy: what should we do after the failure of a first anti-TNF?","volume":"5","author":"Deighton","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ab.2017.11.002_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5069678","article-title":"Evaluation of multiple immunoassay technology platforms to select the anti-drug antibody assay exhibiting the most appropriate drug and target tolerance","volume":"2016","author":"Collet-Brose","year":"2016","journal-title":"J. Immunol. Res."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269717304311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269717304311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T21:20:51Z","timestamp":1757712051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269717304311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":15,"alternative-id":["S0003269717304311"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2017.11.002","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}